Charles Wilson, Ph.D., has been the CEO of Cogent Biosciences, Inc. since March 2014. With a solid background in biotechnology, he brings valuable insights from his previous role as Vice President and Global Head of Strategic Alliances at Novartis, where...

Charles Wilson, Ph.D., has been the CEO of Cogent Biosciences, Inc. since March 2014. With a solid background in biotechnology, he brings valuable insights from his previous role as Vice President and Global Head of Strategic Alliances at Novartis, where he helped bridge research and clinical development. Dr. Wilson earned his Ph.D. in Biophysics from the University of California, San Francisco, which underlines his deep understanding of the science behind drug development. He has led the company through important phases, focusing on genetically defined diseases and innovative therapies. Interestingly, during his tenure, his compensation reflected the company's performance and governance practices, although he did not receive much in bonuses and stock grants, indicating a focus on long-term results. The structure at Cogent includes a separate chair for the board, allowing him to concentrate more on leading the business. His professional history suggests he values collaboration and strategic partnerships, crucial in the fast-evolving biotech field.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Cogent Biosciences, Inc. CEOs

C

Charles Wilson, Ph.D.

Ex-CEO of Cogent Biosciences, Inc.

Field of Expertise

Healthcare & Life Sciences - Biotechnology

Sector of Economy

Healthcare

CEO of Cogent Biosciences, Inc. for

0 years 3 months (Jul 2020 - Oct 2020)

Previous Experience

Unknown

Rivals

Competitors/colleagues of Charles Wilson, Ph.D.

Holdings

See how much did Charles Wilson, Ph.D. make over time.

As for his stock holdings, Dr. Wilson experienced notable ups and downs. At one point, he had a significant amount of his wealth tied up in Cogent stock. His most substantial holdings were when the company’s stock was higher, around...

As for his stock holdings, Dr. Wilson experienced notable ups and downs. At one point, he had a significant amount of his wealth tied up in Cogent stock. His most substantial holdings were when the company’s stock was higher, around the time of new drug developments and strategic partnerships. After his termination in 2020, all stock options expired without vesting, marking a distinct shift in his financial stake in the company. This demonstrates both the risks and rewards of executive positions in biotech, where stock performance can be directly related to innovation timelines and market responses. His previous holdings amounted to substantial shares, although the exact numbers fluctuated significantly, illustrating the volatility inherent in the biotech sector.

Insider Trading

See recent insider trades of Charles Wilson, Ph.D..

No insider trades found for this CEO.

Compensation History

See how much did Charles Wilson, Ph.D. make over time.

In terms of compensation, Dr. Wilson's pay has varied over the years. In 2020, his total compensation was about $1.8 million, which included a salary of $481,340. However, he had no bonus that year and no stock grants were awarded, possibly reflecting the company's strategic decisions at the time. His overall package included a large portion labeled as "other" compensation, mainly cash severance due to his termination. In previous years, he had received bonuses that were performance-based, with a notable cash incentive in 2019 when his total compensation was reported at over $807,000. This pay structure aligns with typical practices in biotech, where executive pay is heavily linked to company performance and strategic milestones achieved.

Year

2020

Total Compensation

$1.80M

Salary

$481.34K

Board Justification

The compensation philosophy aims to align executive compensation with company performance and market benchmarks to retain key talent.

Bonus

$0.00

Board Justification

No bonus was awarded to Dr. Wilson for the year 2020.

Other

$1.32M

Board Justification

This includes cash severance, bonus severance, and COBRA premiums for health benefit coverage following Dr. Wilson's termination.

Restricted Stock

$0.00(0 N/A)

Board Justification

No stock was vested in 2020 as all equity awards held by Dr. Wilson became vested upon his termination.

Performance Metrics

Not specified in the provided proxy statement.

Other Cogent Biosciences, Inc. CEOs

Here are other CEOs of Cogent Biosciences, Inc.

Andrew Robbins

CEO of Cogent Biosciences, Inc.

October 2020 - Present